Wellbutrin

Metastatic Melanoma

PfizerPhase 1Dormant

CC

42/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 73/ 100

Competitive context

87 Active assets in the Metastatic Melanoma cohort.

Asset / Sponsor	Phase	Rating
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd.	Phase 4	BBB
Nivolumab Bristol-Myers Squibb	Phase 4	BB
TIL East Metropolitan Health Service, Australia	Phase 2	BB
Ipilimumab NYU Langone Health	Phase 4	BB
Irinotecan Melanoma and Skin Cancer Trials Limited	Phase 2	BB

View all 50 →

Same molecule, other indications

Wellbutrin is also rated in:

Smoking CessationDormant

A

Indicative ·

82 / 100

DysthymiaDormant

BBB

Indicative ·

73 / 100

depressive disorderDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.